Equity Details
Price & Market Data
Price: $1.85
Daily Change: +$0.184 / 9.92%
Daily Range: $1.66 - $1.89
Market Cap: $268,199,264
Daily Volume: 956,139
Performance Metrics
1 Week: 32.14%
1 Month: 26.71%
3 Months: 6.94%
6 Months: 34.06%
1 Year: 29.37%
YTD: %
About OmniAb, Inc. (OABI)
Discover key statistics for OmniAb, Inc. (OABI). The stock is trading at 1.85, reflecting a daily change of +$0.184 / 9.92%. Its market capitalization is 268,199,264. Review its performance history, including 1-week and 1-year trends.
Company Details
Employees: 89
Sector: Commercial services
Industry: Miscellaneous commercial services
Country: United States
Details
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.